ecancer

What is the relationship between PD-L1 expression and antitumour activity?

Dr Paolo Ascierto - National Tumor Institute, Naples, Italy

19 Nov 2015

Prognostic value of BRAFV600 mutations in stage 3 cutaneous melanoma patients

Prof Philippe Saiag - University of Versailles, Versailles, France

5 Nov 2015

What are the prognostic values of 25-hydroxyvitamin D3 levels at diagnosis and follow-up?

Prof Philippe Saiag - University of Versailles, Versailles, France

5 Nov 2015

Anti-PD1 or tyrosine kinase inhibitors?

Dr Mark Middleton - University of Oxford, Oxford, UK

5 Nov 2015

New drugs and new trials in melanoma

Prof Jean-Jacques Grob - Marseille University, Marseille, France

5 Nov 2015

Highlights of EADO 2015

Prof Jean-Jacques Grob - Marseille University, Marseille, France

5 Nov 2015

Disruptive technologies in cancer

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

5 Nov 2015

Latest from the CoBRIM study

Prof Grant McArthur - Peter MacCallum Cancer Centre, Melbourne, Australia

5 Nov 2015

Anti-PD-1 or anti-CTLA-4 in first line therapy?

Prof Claus Garbe - University of Tübingen, Tübingen, Germany

5 Nov 2015

Long response and long responders in melanoma immunology

Prof Georgina Long - University of Sydney, Sydney, Australia

5 Nov 2015

What is the real role of UV in melanoma?

Dr Amaya Viros - The University of Manchester, Manchester, UK

5 Nov 2015

The Co-BRIM study: Quality-of-life assessment in patients with metastatic melanoma

Prof Brigitte Dreno - Nantes University Hospital, Nantes, France

5 Nov 2015

More from ecancer